Healthcare Third-Party Logistics Market Projected to Exceed USD 522 Billion by 2035
A new forecast from Precedence Research estimates the healthcare third-party logistics market will reach USD 522.87 billion by 2035, reflecting sustained growth across pharmaceutical distribution, medical device handling, and biopharma cold-chain services.
A new market outlook from Precedence Research projects that the healthcare third-party logistics (3PL) sector will surpass USD 522.87 billion in value by 2035, underscoring how outsourced supply chain services are becoming central to the movement of medicines, medical devices, and biologics worldwide. The figure points to a sustained expansion trajectory driven by stricter regulatory requirements, growing pharmaceutical volumes, and the rising complexity of temperature-controlled distribution.
What is driving the growth
Healthcare manufacturers are leaning on specialised logistics partners to handle tasks that fall outside their core operations, including warehousing, order fulfilment, returns management, and last-mile delivery to hospitals, pharmacies, and clinics. Cold-chain handling for vaccines, gene therapies, and other biologics has emerged as a particularly active segment, as temperature excursions can compromise product integrity and trigger costly recalls.
Regulatory pressure is also reshaping demand. Compliance with Good Distribution Practice (GDP) guidelines, serialization rules, and track-and-trace mandates requires infrastructure and documentation that many producers prefer to delegate to experienced 3PL providers.
Implications for shippers and carriers
For pharmaceutical and medical device shippers, the forecast signals continued opportunity to negotiate capacity with third-party partners as outsourced volumes rise. Carriers and integrators, meanwhile, are likely to invest in GDP-compliant facilities, refrigerated fleets, and digital visibility tools to capture share in a market that rewards specialisation over scale alone.
Key segments expected to attract the most investment include:
- Biopharma cold-chain storage and transportation
- Medical device warehousing with serialization support
- Clinical trial logistics and direct-to-patient delivery
- Reverse logistics for expired or recalled healthcare products
As the market matures, broader logistics platforms are also expanding healthcare capabilities, potentially reshaping competition between dedicated pharma 3PLs and large diversified providers entering through partnerships and acquisitions.